2017 – Page 58 – Selby Spine

JULY 19TH, 2017/DATA BRIDGE MARKET RESEARCH

The North America spinal implants devices market is estimated at USD 4.7 billion in 2016 and is projected to reach USD 7.0 billion by 2024, at a CAGR of 5.1% during the forecast period from 2017 to 2024. The new market report contains data for historic year 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

The North America spinal implants market is segmented based on product type, surgery type, procedure type, end-user and geography.

On the basis of product the market is segmented into into spinal fusion, vertebral compression fracture treatment devices and spinal non-fusion. The spinal fusion segment is divided into cervical fusion and thoraco-lumbar fusion. spinal non-fusion devices market is segmented on the basis of product types into dynamic stabilization devices, artificial discs, annulus repair devices and nuclear disc prosthesis. The vertebral compression fracture (VCF) treatment devices are further segmented into two product type balloon kyphoplasty devices and verteboplasty devices.

The North America spinal implants market is also segmented based on procedure type into open surgery and minimally invasive surgeries.

READ THE REST HERE

OVERLAND PARK, KANSAS (PRWEB) JULY 19, 2017

Spinal Simplicity, a medical device company developing innovative solutions to treat complex spinal and orthopedic problems, announces Richard Grant has agreed to serve as an Advisor and will join the Company’s Board of Managers.

Richard Grant brings a wealth of experience to Spinal Simplicity as an accomplished medical device executive with over 30 years in the spinal and orthopedic medical industries. As President, CEO and Co-Founder of Breakaway Imaging, LLC, Mr. Grant successfully developed new imaging technology (the O-Arm), incorporating 2-D (fluoroscopy) and 3-D (CT) imaging, in a mobile platform optimized for orthopedic and spinal surgeries. Mr. Grant orchestrated the sale of Breakaway Imaging, LLC to Medtronic, Inc. in June 2007.

Mr. Grant also has extensive experience with early-stage medical device companies as evidenced by his work as President and CEO of TheraCell, Inc., in Northridge, CA, specializing in stem cell harvesting and processing for orthopedic applications, and, as President of Bonovo Orthopedics in Phoenix, AZ, a US-based company that manufactures and distributes spine and orthopedic instrumentation and implants in China. Mr. Grant currently serves on the Board of Directors of two medical device companies, an orthopedic bracing company and an ortho-biologic company, while also serving as the Chairman of the Board of a company specializing in computer-assisted total knee solutions. Notably, Mr. Grant also served on the Board of Directors of Excelsius Surgical (sold to Globus Medical), Nocimed (partnering with Nuvasive), and Angstrom Medica (sold to Pioneer Surgical).

Todd Moseley, CEO of Spinal Simplicity, applauded Mr. Grant’s significant industry experience stating, “Rich is an admired executive in the spine and orthopedic medical device world. Spinal Simplicity will benefit mightily from Rich’s knowledge and experience navigating early-stage companies from initial innovation to becoming market leaders. Our Company will have the unique advantage of calling upon Rich’s experience as we bring the Minuteman G3-R to the minimally-invasive spine market to enhance posterior supplemental fixation and fusion, as well as to introduce our ground-breaking Wolff’s Law™ plating technology to the spinal and orthopedic extremities market.”

Mr. Grant agreed that this is an extraordinary time for Spinal Simplicity, “As the Company experiences the positive responses being lauded by physicians to its revolutionary technology, it becomes more and more evident that the spinal and orthopedic markets are ready for innovative medical devices. The time is ripe to get the word out about the innovation being unveiled by Spinal Simplicity.”

Spinal Simplicity’s Minuteman® family of sterile-packed, posterior, non-pedicle supplemental fusion and fixation devices for use in the non-cervical spine (T1-S1) provides an alternative to traditional fixation, such as pedicle screws. The Minuteman® family of devices consists of a plating system intended for supplemental fusion in patients with degenerative disc disease, spondylolisthesis, trauma and tumor.

About Spinal Simplicity
Spinal Simplicity, LLC, headquartered in Overland Park, Kansas, is dedicated to the creation of simple solutions for the treatment of complex spinal and orthopedic problems. Spinal Simplicity has regulatory clearance for the Minuteman® system in the US, Europe, and Canada. Our vision is to be the leader in innovative, simplified surgical solutions, while delivering uncompromising quality. For more information, please visit http://www.spinalsimplicity.com.

ATLANTA, GA–(Marketwired – Jul 19, 2017) – Medovex Corp. (NASDAQ: MDVX) (“Medovex” or the “Company”), a developer of medical technology products, today announced the first human cases performed using its recently launched DenerveX™ System and first revenue events.

The DenerveX System which has recently received CE Mark approval and clearance for commercialization in the European countries, is a new and novel device designed for enduring relief of Facet Joint Syndrome related to lower back pain.

Jarrett Gorlin, Medovex CEO stated, “Our first human use cases for the DenerveX System which took place in Manchester, England recently with very encouraging initial procedural success. We anticipate performing up to as many as 30 plus additional procedures by the end of August. This is the beginning of delivering on our goal of ‘proof of principle’ in the adoption of the technology in this very sizable market.” Gorlin concluded, “We are also pleased to have also reached our first revenue events in the EU with others soon to expected to follow.”

The DenerveX System offers a fast and simple way to perform a safe Facet Joint Syndrome treatment.

Patrick Kullmann, Medovex President and COO., added, “With the DenerveX™ System, we can offer surgeons and pain management specialists the ability to attain precise treatment of the Facet Joint pain. The DenerveX treatment uses ‘Rotacapsulation™,’ a combination of high heat and rotational capsular tissue shaving, in a minimally invasive posterior procedure for the treatment of Facet Joint Syndrome. The DenerveX System offers an alternative to existing treatments only providing temporary relief.”

Facet Joint Syndrome (FJS), also known as spinal osteoarthritis, spinal arthritis, or facet joint osteoarthritis, is a significant health and economic problem in the United States and other countries in the EU and Rest of World affecting millions each year. Current treatment options are generally temporary and there is no proven long-lasting option for FJS.

The DenerveX System is a highly differentiated technology. It denervates and removes capsular tissue from the Facet Joint in one single procedure. Treatment results from the combined effect of a deburring or polishing action and RF ablation treatment on the Facet Joint. Using this new technique, the slowly rotating burr removes the targeted facet joint synovial membrane and joint surface while the heat ablation destroys tissue and denudes any residual nervous and synovial membrane overlying the joint, removing the end point sensory tissue of the joint.

The DenerveX System consists of the DenerveX Kit which contains the DenerveX Device, a single use medical device and the DenerveX Pro-40 Power Generator. DenerveX system is not yet FDA cleared.

About Medovex
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company’s first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com

Safe Harbor Statement
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the Securities and Exchange Commission (the “SEC”), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

CONTACT INFORMATION

CONTACT INFORMATION
Medovex Corp.
Jason Assad
470-505-9905
Email Contact

FREMONT, CA–(Marketwired – July 19, 2017) – PathPartner Technology Inc., a technology enabler in developing intelligent systems, announces a successful cadaveric study of Arthromeda’s (www.arthromeda.com) innovative patient-specific hip alignment navigation product, Arthrosight-PS™.

In a recent press release, Arthromeda Inc., a developer of intelligent orthopedic navigation systems, announced the successful completion of cadaveric studies demonstrating the efficient performance of Arthrosight-PS™ at the Cincinnati Children’s Hospital and Medical Center (CCHMC, Cincinnati, OH). These cadaveric studies confirmed that the patient-specific Arthrosight-PS™ Hip Alignment System is an intuitive, all-in-one system for accurate implant positioning and providing real-time position angles (inclination and anteversion), leg-length and femoral offset difference measurements.

With an increase in the number of hip procedures, and 80% of them being represented by Total Hip Arthroplasty¹; technology serves as a panacea to improve surgical methodologies and also as an enabler towards enhanced outcomes of surgeries. Accurate hip implant positioning is an extremely important criterion for patients, physicians, regulators and device companies. A device that enables the surgeons to perform accurate hip arthroplasty procedures with minimal interference in their work-flow is the need of the hour and this is being ably addressed by Arthrosight-PS™.

This was the result of an intense and ingenious design process, fabricated from Arthromeda’s intellectual property combined with their design input specifications and our talented team spanning the entire electronics engineering space that included hardware design, algorithms, firmware and application developments. PathPartner, with its vast experience in delivering state-of-the-art technologies from ideation to complete system solutions, provided critical support to build the platform that included MEMS sensors, laser sensors, photodiodes, wireless connectivity, Android applications and cloud solutions to provide an easy-to-use device in the operation-room offering accurate angular positioning (inclination and anteversion) and leg-length/femoral offset difference measurements.

“PathPartner has been a valuable partner to Arthromeda,” commented PJ Anand, Executive Chairman and Co-Founder of Arthromeda. “We fully intend to leverage this relationship with the PathPartner team to expand the platform into knee and shoulder procedures.”

“The joint positioning system that offers four key measurements (with an accuracy of 2 degrees for inclination/anteversion and 2 millimeters for leg-length/femoral offset difference), without the need for costly capital equipment, is a game changer in helping surgeons and patients in hip arthroplasty procedures,” commented PathPartner Technology Senior Vice President Raman Narayan.

1: Source: Third Annual report of AJRR (American Joint Replacement Registry)

About PathPartner Technology

PathPartner offers design, development and integration services in advanced embedded technology. Based out of Fremont, Calif., PathPartner Technology Inc is an affiliate of PathPartner Technology Pvt. Ltd., Bangalore, India.

With an unparalleled experience in transforming innovative ideas into full-fledged products, PathPartner provides its clients the advantage of top-of-the-line technologies, superior performance and faster time-to-market options. Having the expertise in BSP & device drivers, multimedia codecs, algorithms, imaging and hardware design, PathPartner is geared for technology driven execution and quality delivery for corporations across industries including automotive, semiconductor, healthcare, cameras and surveillance.

More information is available at www.pathpartnertech.com.

CONTACT INFORMATION

Contact:
Raman Narayan
Phone: 408-242-7411
Email: raman.narayan@pathpartnertech.com
Website: www.pathpartnertech.com

Emily Mongan, Staff Writer/July 17, 2017

The Centers for Medicare & Medicaid Services released two proposals last week that may change where beneficiaries receive joint replacements, and how accountable care organizations deal with the agency’s three-day stay rule waiver.

The first proposal, contained within a proposed rule concerning hospital outpatient prospective payments, would allow Medicare to cover knee replacement surgeries in outpatient facilities.

Research on conducting the procedures in outpatient settings has shown outpatients did not experience higher complication or readmission rates than inpatients, CMS said. If the rule were to be enacted, beneficiaries would still be able to undergo the procedures in an inpatient setting “based on the beneficiary’s individual clinical needs and preferences,” the agency said.

CMS also is soliciting public comment on possibly doing the same with hip replacements.

READ THE REST HERE

HONG KONG (PRWEB) JULY 19, 2017

OrthAlign, Inc., a privately held U.S.-based medical device and technology company providing orthopedic surgeons with advanced precision technologies, announced today the first KneeAlign® cases completed for total knee arthroplasty (TKA) in Hong Kong. These cases were completed by Hong Kong-based orthopaedic surgeon Professor Kevin K.W. Ho at Prince of Wales Hospital, one of the country’s leading public hospitals, in collaboration with OrthAlign’s local distribution partner Smith & Nephew Hong Kong.

OrthAlign provides highly accurate, computer-assisted, handheld technologies for surgeons to receive real-time, actionable data for precise alignment and positioning of components in total knee, unicondylar knee, and total hip (both posterior and anterior) arthroplasty surgeries. Over 15 peer-reviewed clinical studies have been published to date, validating OrthAlign’s accuracy, simplicity of use, and benefits in recovery for the patient.

Professor Ho stated, “KneeAlign is large console navigation in a small, handheld box. The technology is so easy to use and gives me accurate information that I need, all within the sterile field, without all of the hassles and extra costs that large console computer assisted surgery systems require. I was pleased with my first set of cases and will continue using it because I believe it is valuable for my practice in providing the best possible outcomes for my patients.”

“Navigation plays a very important role in Hong Kong’s joint arthroplasty market,” said Priscilla Chan, General Manager of Smith & Nephew Hong Kong & Taiwan. “Surgeons and hospital facilities believe in navigation, but cost and operational inefficiencies have been key barriers in adoption optimization. I believe OrthAlign provides a revolutionary technology that addresses those barriers and will finally give Hong Kong a product that can be accessible by every hospital and surgeon. We look forward to growing the business through our partnership with OrthAlign.”

In a published TKA clinical study by Denis Nam, M.D. (Rush University Medical Center, Chicago, IL), significant differences favoring the use of KneeAlign vs. conventional Computer Assisted Surgery were found with regard to the accuracy of femoral component alignment, with 94.9% of patients in the KneeAlign cohort having an alignment within 2° of neutral vs. 92.5% in the CAS cohort. There was also a significant difference in overall mean mechanical alignment of the limb, with 92.5% of patients within 3° of neutral mechanical axis in the KneeAlign cohort vs. 86.3% in the CAS cohort.

In another study by Dr. Nam (conducted as a randomized controlled trial, consisting of five different surgeons), it was found that KneeAlign decreases the incidence of outliers for tibial component alignment in both the coronal and sagittal planes, and improves the surgeon’s ability to achieve a specific, intraoperative goal, compared to conventional, tibial extramedullary (EM) alignment guides in TKA. In the KneeAlign cohort, 95.7% of tibial components were within 2° of perpendicular to the tibial mechanical axis and 95% of tibial components were within 2° of a 3° posterior slope (compared to 68.1% and 72.1% in the EM cohort, respectively).

“Hong Kong’s orthopaedic market may be one of the most fascinating in the world,” said James Young Kim, OrthAlign’s Vice President and General Manager of International. “There are so many dynamics in the marketplace, such as public vs. private hospitals, long queues for patients who are on 3-year waiting lists for their total knee arthroplasties, and a strong desire for technology by surgeons. Without question, hospitals and surgeons value navigation technology, and OrthAlign will be the best option for them, not only from a price point, but also in terms of accuracy and operational workflow. As OrthAlign continues to focus on its mission in expanding customer reach, we welcome Hong Kong to the growing OrthAlign family and look forward to working with Smith & Nephew Hong Kong in providing local hospitals, surgeons, and patients our technology.”

About OrthAlign, Inc.

OrthAlign is a privately held medical device and technology company, developing advanced technologies that deliver healthier and more pain-free lifestyles to joint replacement patients, globally. We provide healthcare professionals with cutting edge, computer-assisted surgical tools that seamlessly and cost-effectively deliver vital data and clinical results to optimize outcomes for our patients. For more information regarding OrthAlign, please visit http://www.orthalign.com.

“ORTHALIGN®, ORTHALIGN PLUS®, KNEEALIGN®, KNEEALIGN® 2, HIPALIGN®, and UNIALIGN™ are registered trademarks of OrthAlign, Inc.”

Paxeon Reconstruction, a manufacturer of best-in-class orthopedic products including derivative and emerging products, announces that has received full clearance to introduce the Genius Knee to the marketplace.

In today’s orthopedic environment, it is important that companies not only provide quality products but also financially beneficial products. With that in mind, Paxeon Reconstruction has created a unique Value Solutions Program that has provided hospitals over $1.3m in savings through its first 12-months of clinical use. Physicians that have utilized Paxeon’s Total Hip Products have saved on average $1,315.00 per case.

Kyle Sineath, President of Paxeon Reconstruction said: “The addition of this total knee to our already proven hip implants is an exciting milestone for Paxeon. We look forward to adding the Genius Knee to our very successful Value Solutions Program to extend savings throughout the total joint continuum of care.”

About Paxeon Reconstruction

Paxeon Reconstruction builds best-in-class orthopaedic products, including derivative and emerging products. We collaborate with hospitals, health systems and physicians to create alignment and utilization of value-based solutions combined with efficiency models for today’s changing healthcare environment. Paxeon Reconstruction offer the world’s most comprehensive portfolio of orthopaedic products and services for joint reconstruction. Paxeon Reconstruction has a celebrated clinical history, and has evolved to meet the needs of the changing orthopaedics marketplace. The history that weaves the fabric of the Paxeon Reconstruction is one that is rich with innovation and demonstrates sustained leadership in an ever-changing landscape of patient and professional needs.

ROSEMONT, Ill., July 19, 2017 /PRNewswire-USNewswire/ — During the summer months, many children are drawn to indoor and outdoor trampolines for fun and physical activity. And yet, trampolines can be extremely dangerous, especially for children under age 6.

In 2015, there were more than 295,000 medically treated trampoline injuries in the U.S., according to the Consumer Product Safety Commission, including 102,943 emergency department visits.

“We want children to enjoy exercise and physical activity, especially during the summer months,” said AAOS spokesperson and Los Angeles pediatric orthopaedic surgeon Jennifer M. Weiss, MD, “but parents and caregivers should know about the dangers of trampolines and the risk for serious injury, especially in very young children. Children younger than age 6 are less likely to have the coordination, body awareness, and swift reaction time necessary to keep their bodies, bones and brains safe on trampolines.”

The dangers of trampoline use were recently highlighted when a 3-year-old Florida boy broke his femur (thigh bone) during routine jumping on a trampoline, requiring a full lower body cast, and causing him tremendous pain and discomfort.

The most common trampoline injuries are sprains and fractures resulting from falls on the trampoline mat, frame or springs; collisions with one or more jumpers; stunts gone wrong; and falls off the trampoline on the ground or other hard surface, according to CPSC.

As highlighted in the American Academy of Orthopaedic Surgeons’ position statement, “Trampolines and trampoline safety,” nearly one-third of trampoline injuries involved fractures; 60 percent of the fractures were located in the upper extremities and approximately 36 percent in the lower extremities. In addition:

Most trampoline injuries occur in the home environment, and more than 90 percent are sustained by children, usually those between the ages of 5 and 14 years. Although most injuries to children occur while they are unsupervised by parents or adults, many also occur when adults are present. More than half of injuries occur on the mat of the trampoline and three-fourths of injuries involve two or more children on the trampoline at the same time.

There is no data that shows a reduction in injury rates for trampolines outfitted with netting and/or other safety equipment.

The American Academy of Orthopaedic Surgeons recommends that parents and caregivers ensure the following to minimize and avoid trampoline injuries:

Do not allow children younger than 6 years of age to use trampolines.
Provide careful adult supervision, proper safety measures and instruction when trampolines are used for physical education, competitive gymnastics, diving training, and other similar activities.
Allow only one participant at a time to use a trampoline.
Ensure that spotters are present when participants are jumping. Somersaults or high-risk maneuvers should be avoided without proper supervision and instruction; these maneuvers should be attempted only with proper use of protective equipment, such as a harness.
Place the trampoline-jumping surface at ground level.
Ensure that supporting bars, strings, and surrounding landing surfaces have adequate protective padding that is in good condition and appropriately placed.
Regularly check equipment for safety conditions; discard worn or damaged equipment if replacement parts are unavailable
Do not rely on safety net enclosures for injury prevention; most injuries occur on the trampoline surface.
Remove trampoline ladders after use to prevent unsupervised access by young children.

More Information about the AAOS
With more than 39,000 members, the American Academy of Orthopaedic Surgeons is the world’s largest medical association of musculoskeletal specialists. The AAOS provides educational programs for orthopaedic surgeons and allied health professionals, champions and advances the highest quality musculoskeletal care for patients, and is the authoritative source of information on bone and joint conditions, treatments and related issues.

Visit AAOS, at:
Newsroom.aaos.org for bone and joint health news, stats, facts, images and interview requests.
ANationinMotion.org for inspirational patient stories, and orthopaedic surgeon tips on maintaining bone and joint health, avoiding injuries, treating musculoskeletal conditions and navigating recovery.
Orthoinfo.org for patient information on hundreds of orthopaedic diseases and conditions.
Facebook.org/AAOS1
Twitter.com/AAOS1

CONTACT: Kelly King Johnson, 847-384-4033, king@aaos.org; Sheryl Cash, 847-384-4032, scash@aaos.org

July 19, 2017

SUNNYVALE, Calif.–(BUSINESS WIRE)–Simplify Medical Pty Ltd, maker of the Simplify® cervical artificial disc, today announced the closing of a Series B financing of $21 million. LSP (Life Sciences Partners) led the round, with additional investment from Sectoral Asset Management and returning investor M.H. Carnegie. The new funds will be used to complete two ongoing U.S. pivotal clinical trials of the Simplify Disc studying its use in one level of the spine and in two adjacent levels of the spine as a treatment for cervical degenerative disc disease.

“We are gratified by the confidence investors are showing in our Simplify Disc, which is designed to be clearly viewed on MRI without the artifact that can result from metal used in typical spine implants. By avoiding the radiation that would otherwise accompany a computed tomography (CT) scan, we intend to minimize patient exposure to unnecessary radiation risk,” said Simplify Medical Chief Executive Officer David Hovda. “The new funds will enable us to develop the rigorous evidence that gets us one step closer to availability for U.S. patients in need.”

“We are very impressed with the intelligence of the Simplify Disc technology,” said LSP General Partner Dr. Fouad Azzam. “With hospitals being held to higher standards relative to complications and post-operative costs, it is important that innovations minimize patient risk. Not only does the Simplify Disc avoid substantial radiation exposure, it also avoids metal wear that has been problematic for other orthopedic devices. In addition, it offers the lowest-profile device available, opening up a broader patient population for the technology.”

While magnetic resonance imaging (MRI) is widely used pre-operatively for surgical planning, spine surgeons often switch to CT post-operatively in order to accommodate metal components, which can make it difficult to view the devices, as well as the facets and adjacent levels. However, CT scans have been shown to expose patients to ionizing radiation that equates to 400 to 550 chest X-rays per scan.

Two Simplify Disc U.S. pivotal trials are currently enrolling. The two-level, prospective pivotal trial will encompass up to 200 patients at up to 15 centers, comparing cervical implantation of the device in two contiguous discs from C3 to C7 with two-level cervical fusion surgery. The other pivotal trial is studying one-level cervical implantation of the device between C3 to C7 with cervical fusion surgery from a historical nonconcurrent control group. For information about eligibility or enrollment in either pivotal trial, please visit http://www.simplifytrial.com/.

The Simplify Disc has received the CE Mark and has been used to treat more than 700 patients outside the U.S. over the last three years. Early clinical data has shown substantial improvement in patient pain scores and functional improvement after treatment.

ABOUT SIMPLIFY MEDICAL

Simplify Medical is focused on cervical spinal disc arthroplasty, using innovative, MRI-friendly materials designed to decrease the need for ionizing radiation and enhance patient options. Simplify Medical is located in Sunnyvale, California. To learn more, visit http://www.simplifymedical.com/.

Caution: The Simplify Disc is an investigational device in the United States and is limited by law to investigational use.

Contacts

Chronic Communications, Inc.
Michelle McAdam, 949-545-6654
michelle@chronic-comm.com

July 18, 2017

PARIS–(BUSINESS WIRE)–EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI – Eligible PEA – SME), the pioneer of orthopaedic medical imaging, 2D/3D, today announced its (non-audited) consolidated revenue for the first semester ended June 30, 2017.

Marie Meynadier, Chief Executive Officer of EOS imaging, commented: “We continue to experience positive commercial dynamics in the EMEA and Asia-Pacific regions. This was a key driver of our performance during the first half of 2017, in line with our global market expansion strategy. We also benefitted from the strong growth of EOS system service contracts, which contributes to the recurring revenue component of our business. In North America, we have appointed Mike Lobinsky to the newly created position of President North America. In this role, he will lead our global North American operations, providing a stronger leadership presence with a focus on accelerating commercial activities, particularly in the U.S., which is one of the most important markets for the Company. Based on the strength of our business in the EMEA and Asia-Pacific, along with our recent initiatives to invigorate the activity in North America, we are confident that we will see an acceleration in global adoption of the EOS solutions.”

Revenue for the First Half 2017

€ millions

H1 2017

H1 2016

% change

Equipment sales

13.15

11.45

+15%

As a % of total revenues

80%

81%

Sales of maintenance

2.83

2.22

+28%

As a % of total revenues

17%

16%

Sales of consumables and services

0.49

0.46

+4%

As a % of total revenues

Total revenues

16.46

14.14

+16%

Unaudited data

In the first half of 2017, the Company generated a revenue of €16.5 million, up 16% compared to the first half of 2016. The Company sold 34 EOS® systems during the first half of the year, compared to 28 systems in the same period last year. Sales of maintenance contracts increased by 28% to €2.84 million, reflecting the continued growth of the installed base of EOS systems under contract.

The increase in revenues over the first half of 2017 was driven by strong sales in the EMEA and Asia-Pacific regions, partially offset by lower sales in North America, related to an operational reorganization.

€ millions	H1 2017	H1 2016	% change
EMEA	7.39	5.36	+38%
North America	5.74	7.66	-25%
Asia-Pacific	3.34	1.12	+197%
Total revenues	16.46	14.14	+16%
Unaudited data

Revenue grew by 38% in EMEA, primarily driven by results from the United Kingdom and France, where the Company recently installed its 50^th EOS system, demonstrating its ability to achieve a significant adoption in its target market.

Revenues tripled in Asia-Pacific, reflecting rapid adoption of the EOS system, particularly in the Chinese and Australian markets.

In North America, revenues declined by 25%, as the Company continued to expand its installed base, predominantly in its existing network of client hospitals.

Revenue for the Second Quarter 2017

€ millions

2017

2016

Equipment sales

5.47

7.67

4.09

7.36

As a % of total revenues

77%

82%

76%

83%

Sales of maintenance contracts

1.40

1.43

0.99

1.23

As a % of total revenues

19%

15%

19%

14%

Sales of consumables and services

0.26

0.23

0.24

0.22

As a % of total revenues

Total revenues

7.13

9.34

5.33

8.82

Unaudited data

In the second quarter of 2017, EOS imaging achieved revenue of €9.34 million, up 6% compared to the second quarter of 2016. The Company sold 20 EOS systems in the quarter and continued to increase in the installed base of EOS systems under maintenance contracts.

About EOS imaging

EOS imaging designs, develops, and markets EOS®, an innovative medical imaging service dedicated to osteo-articular pathologies and orthopaedics, as well as the associated solutions. The Company is authorized to market in 51 countries, including the United States (FDA), Japan, and the European Union (EC). The Group posted revenues of €30.8 million and employs 132 people at December 2016, including an R&D team of 43 engineers. The group is based in Paris and has five subsidiaries: in Besançon (France), Cambridge (Massachusetts), Montreal (Canada), Frankfurt (Germany) and Singapore.

EOS imaging has been selected to integrate the EnterNext © PEA – SME 150 index, composed of 150 French, listed companies on the Euronext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

Next press release: 2017 Half-Year Results, September 8, 2017 (after market close)

Contacts

EOS imaging
CFO
Pierre Schwich, +33 (0)1 55 25 61 24
investors@eos-imaging.com
or
NewCap
Financial communication and investor relations
Pierre Laurent, +33 (0)1 44 71 94 96
eosimaging@newcap.eu
or
The Ruth Group (US)
Press relations
Joanna Zimmerman, 646-536-7006
jzimmerman@theruthgroup.com

Newer Posts

Older Posts

Search

3 days / 6 sessions
Current Issues in Spine

North America Spinal Implants Market CAGR of 5.1% 2024

Richard Grant joins Spinal Simplicity, LLC as an Advisor and to serve on the Board of Managers

Medovex Announces First Human Cases Using Its DenerveX Device and First Revenue Events

CONTACT INFORMATION

PathPartner Technology Contributes to Arthromeda’s Successful Preclinical Study of Arthrosight-PS™ Hip Alignment Navigation System

CONTACT INFORMATION

CMS proposes Medicare coverage for outpatient joint replacements, changes to SNF 3-day stay rule

OrthAlign, Inc. Announces First KneeAlign Cases for Total Knee Arthroplasty in Hong Kong

Paxeon Reconstruction Adds the Genius Knee to its Disruptive Savings Model After Receiving FDA Clearance

Orthopaedic surgeons warn parents and young children about the dangers of trampolines

Simplify Medical Closes $21 Million Series B Financing to Support Innovative Cervical Artificial Disc

Contacts

EOS imaging Reports 16% Revenue Growth for the First Half 2017

Contacts

STAR Ankle Joint Replacements Last Long Term and Provide Relief for Patients

Medacta USA’s Spine Division Begins 2017 with Key Appointment, Significant Growth

Spinal Stabilization Technologies Announces Start of LOPAIN 2 Clinical Trial in South America for Lumbar Degenerative Disc Disease

$250K Pediatric Device Competition Now Accepting Proposals

First Single-Use Rigid Endoscope to be Demonstrated at AAOS